Sweetland et al v. GlaxoSmithKline Inc.
Nova Scotia Supreme Court File: Hfx No. 315567
A proposed national settlement has been reached. A copy of the Settlement Agreement is available in PDF in English or French. Please review the following notice to learn more about the proposed settlement:
NOTICE OF CERTIFICATION AND SETTLEMENT
APPROVAL HEARING IN THE CANADIAN AVANDIA LITIGATION
Read this Notice carefully as it may affect your rights
NOTICE OF CERTIFICATION AND SETTLEMENT
A Canada-wide settlement has been reached in the Avandia Class Action. The Class Action sought compensation for cardiovascular injuries which were allegedly related to the use of Avandia. The Defendants deny the allegations made in the lawsuits and make no admission as to the truth of these allegations. Class Counsel is aware of additional similar Avandia litigation in Canada, a list of which may be accessed online at: www.avandiaclassaction.com. The settlement, if approved, will also resolve these actions.
THE SETTLEMENT REQUIRES COURT APPROVAL
In order for the Settlement to become effective, it must be approved by the Supreme Court of Nova Scotia. The Court must be satisfied that the Settlement is fair, reasonable and in the best interest of the Class. The Settlement Approval Hearing is scheduled for January 29, 2019 at 9:30 a.m. at The Law Courts Building, 1815 Upper Water Street, Halifax, Nova Scotia.
WHO IS INCLUDED IN THE CLASS ACTION?
If approved, the Settlement applies to: (a) All persons in Canada, including their estates, who were prescribed and ingested Avandia (the “Primary Class”); and (b) the spouses (including common-law spouses and same-sex spouses), children, grandchildren, parents, grandparents and siblings of deceased members of the Primary Class (the “Family Class”).
WHO REPRESENTS THE CLASS?
Albert Carl Sweetland & Barbara Fontaine, c/o Wagners.
WHAT IF I DON’T WANT TO BE IN THE CLASS ACTION?
If you are a Primary or Family Class Member and do not wish to be bound by the Class Action and/or by the Settlement (if approved), you must Opt Out. To Opt Out, you must fully complete and submit an Opt Out Form to Wagners by the Opt Out Deadline of January 15, 2019. Opt Out Forms are available at www.avandiaclassaction.com or may be requested from Class Counsel. If you Opt Out, you will not be able to make a claim for compensation under the Settlement.
WHAT SETTLEMENT HAS BEEN REACHED FOR THE CLASS ACTION?
The Settlement provides for a Minimum Settlement Amount of $4,116,666.67 (CND) and up to a Maximum Settlement Amount of $6,750,000.00 (the “Settlement Payment”), depending on the number of approved claims. The Settlement Payment will be used to pay compensation for Approved Claimants, the claims of provincial health insurers, the costs of notice and administration and Class Counsel Legal Fees. Approved Claimants must satisfy the eligibility criteria set out in the Compensation Protocol. You can review the Settlement documents by contacting Class Counsel or visiting the settlement website at www.avandiaclassaction.com.
Compensation is available for Class Members who used Avandia for at least thirty continuous days commencing before December 2010 and who suffered one of the following injuries within no more than year of such use: myocardial infarction (heart attack), congestive heart failure, coronary artery bypass graft (CABG surgery), and percutaneous coronary intervention with stent placement. Other eligibility considerations described in the Settlement Agreement will affect how much compensation you receive.
PARTICIPATION IN THE SETTLEMENT
If the Settlement is approved, you must submit a Claim Form by the Claims Deadline. Information about how and when to apply for settlement funds will be provided in a future notice and will be posted online at: www.avandiaclassaction.com.
FURTHER DOCUMENTATION AVAILABLE DECEMBER 15, 2018
No later than December 15, 2018 the documents being filed by Class Counsel in relation to the Settlement Approval Hearing and the motion to approve Class Counsel’s fees will be available on the settlement website at: www.avandiaclassaction.com.
OBJECTING TO THE SETTLEMENT AND OPPORTUNITY TO APPEAR
If you wish to object to the Settlement, you may submit a written objection, referencing Hfx. No. 315567, to the Supreme Court of Nova Scotia at The Law Courts, 1815 Upper Water Street, Halifax, Nova Scotia, B3J1S7, with a copy to Wagners at the address below, to be sent no later than January 15, 2019. You may also attend the Settlement Approval Hearing and you may make oral submissions to the Court.
At the Settlement Approval Hearing, Class Counsel will make a separate motion requesting approval for payment of fees, disbursements and applicable taxes. Class Counsel have pursued this lawsuit on a contingency basis, which provides for payment of legal fees of 25% of the total value of the settlement plus applicable taxes, as well as recovery of out of pocket expenses, and Class Counsel will seek approval from the Nova Scotia Court for such payment in accordance with the terms of their retainer agreement. The total value of the settlement depends on the number of approved claims. The maximum amount of legal fees for which Class Counsel will seek approval will be $1,687,500 (25% of the maximum settlement amount of $6,750,000) plus applicable taxes of 15%. If less than the maximum settlement amount is reached, Class Counsel will seek approval of a lower amount, i.e. 25% of the settlement amount paid, plus applicable taxes of 15%. The estimated maximum amount of disbursements for which Class Counsel will seek approval is approximately $400,000, representing the out of pocket expenses incurred by Class Counsel. This excludes future costs of notice and claims administration, for which the Defendants have agreed to contribute up to $250,000 out of the Maximum Settlement Amount.
OBJECTING TO LEGAL FEES AND OPPORTUNITY TO APPEAR
If you wish to object to Class Counsel’s fees, you may submit a written objection, referencing Hfx. No. 315567, to the Supreme Court of Nova Scotia at The Law Courts, 1815 Upper Water Street, Halifax, Nova Scotia, B3J 1S7, with a copy to Wagners at the address below, to be sent no later than January 15, 2019. You may also attend the hearing to approve Class Counsel’s fees, and you may make oral submissions to the Court.
There is no charge to speak with Class Counsel.
This Notice has been approved by the Supreme Court of Nova Scotia.
AVIS D’AUTORISATION ET D’APPROBATION DU RÈGLEMENT
DANS LE CADRE DU RECOURS CANADIEN AVANDIA
Veuillez lire cet avis attentivement car il pourrait avoir une incidence sur vos droits
AVIS D’AUTORISATION ET DE RÈGLEMENT
Un règlement pancanadien a été conclu dans le cadre de l’action collective Avandia. L’action collective vise à obtenir une indemnité pour des blessures cardiovasculaires prétendument liées à l’utilisation d’Avandia. Les Défenderesses nient les allégations formulées contre elles dans les Procédures et ne font aucune admission quant à la véracité de ces allégations. Les Avocats du Groupe sont informés de d’autres recours similaires et relatifs à l’Avandia au Canada, une liste de ceux-ci peut être consultée en ligne au fr.avandiaclassaction.com. Le Règlement, s’il est approuvé, mettra également fin à ces recours.
LE RÈGLEMENT NÉCESSITE L’APPROBATION DU TRIBUNAL
Afin que le Règlement entre en vigueur, celui-ci devra être approuvé par la Cour suprême de la Nouvelle-Écosse. Le Tribunal devra être d’avis que le Règlement est juste, raisonnable et dans le meilleur intérêt du Groupe. L’Audience d’Approbation du Règlement aura lieu le 29 janvier 2019, à 9h30, au Palais de justice situé au 1815, Upper Water Street, à Halifax, en Nouvelle-Écosse.
QUI EST VISÉ PAR CETTE ACTION COLLECTIVE?
Si le Règlement est approuvé, celui-ci visera : (a) toutes les personnes au Canada, y compris leurs successions, qui se sont vues prescrire et qui ont consommé l’Avandia (le « Premier Groupe »); ainsi que (b) les époux (y compris les conjoints de fait et les époux du même sexe), les enfants, les petits-enfants, les parents, les grands-parents et les frères et sœurs des membres décédés du Premier Groupe (le « Groupe de la Famille »).
QUI SONT LES REPRÉSENTANTS DU GROUPE?
Albert Carl Sweetland & Barbara Fontaine, a/s Wagners.
QU’ARRIVE-T-IL SI JE NE VEUX PAS FAIRE PARTIE DE L’ACTION COLLECTIVE?
Si vous êtes un membre du Premier Groupe ou du Groupe de la Famille et que vous ne souhaitez pas être lié par l’action collective et/ou par le Règlement (s’il est approuvé), vous devez vous exclure. Pour vous exclure, vous devez remplir entièrement et soumettre un Formulaire d’Exclusion à Wagners avant la date limite pour s’exclure, soit le 15 janvier 2019. Les Formulaires d’Exclusion sont disponibles au fr.avandiaclassaction.com ou peuvent être demandés aux Avocats du Groupe. Si vous vous excluez, vous ne pourrez pas déposer une réclamation pour obtenir une indemnité en vertu du Règlement.
QUELLE ENTENTE DE RÈGLEMENT A ÉTÉ CONCLUE DANS L’ACTION COLLECTIVE?
Le Règlement prévoit un Montant de Règlement Minimum de 4 116 666.67$ CAN et un Montant de Règlement Maximum de 6 750 000$ (le «Montant de Règlement»), variant en fonction du nombre de réclamations approuvées. Le Montant de Règlement sera utilisé afin de payer les indemnités des Réclamants Admissibles, les réclamations des assureurs-santé provinciaux, le coût des avis et de l’administration et les honoraires des Avocats du Groupe. Les Réclamants Admissibles devront satisfaire les critères prévus au Protocole d’indemnisation. Vous pouvez consulter les documents relatifs au Règlement en contactant les Avocats du Groupe ou en visitant le site internet du Règlement au fr.avandiaclassaction.com.
Une indemnité est disponible pour les Membres du Groupe qui ont utilisé l’Avandia pendant au moins trente jours consécutifs, et ce, avant décembre 2010 et qui ont souffert de l’une des blessures suivantes au plus tard un an suivant l’utilisation: infarctus de myocarde (crise cardiaque), insuffisance cardiaque congestive, pontage aortocoronarien et intervention coronarienne percutanée avec mise en place d’une endoprothèse vasculaire. D’autres critères d’admissibilité décrits dans le Règlement feront varier le montant de l’indemnité que vous pourriez recevoir.
PARTICIPER AU RÈGLEMENT
Si le Règlement est approuvé, vous devrez soumettre un Formulaire de Réclamation à l’Administrateur des Réclamations avant la Date limite des réclamations. Des informations concernant la façon et le moment de déposer une réclamation pour obtenir une indemnité provenant des fonds de règlement seront transmises dans un avis ultérieur et seront publiées en ligne au fr.avandiaclassaction.com.
DOCUMENTATION ADDITIONNELLE DISPONIBLE LE 15 DÉCEMBRE 2018
Au plus tard le 15 décembre 2018, les documents déposés par les Avocats du Groupe concernant l’Audience d’Approbation du Règlement et la demande visant à faire approuver les honoraires des Avocats du Groupe seront disponibles sur le site internet du Règlement au fr.avandiaclassaction.com.
S’OPPOSER AU RÈGLEMENT ET POSSIBILITÉ DE SE PRÉSENTER DEVANT LE TRIBUNAL
Si vous désirez vous opposer au Règlement, vous devez transmettre votre opposition par écrit, portant comme référence Hfx. No. 315567, à la Cour suprême de la Nouvelle-Écosse, au Palais de Justice situé au 1815, Upper Water Street, à Halifax (Nouvelle-Écosse), B3J 1S7 et en transmettre une copie à Wagners, à l’adresse indiquée ci-dessous, et ce, au plus tard le 15 janvier 2019. Vous pouvez également assister à l’Audience d’Approbation du Règlement et vous pourrez présenter vos observations oralement devant le Tribunal.
HONORAIRES ET DÉBOURSÉS
Lors de l’Audience d’Approbation du Règlement ou à la suite de celle-ci, les Avocats du Groupe demanderont, dans une demande séparée, le paiement de leurs honoraires, de leurs déboursés et des taxes applicables. Les Avocats du Groupe ont accepté d’entreprendre ce recours sur la base d’une rémunération à pourcentage, laquelle prévoit que ceux-ci pourront recouvrer 25% de la valeur du Règlement, plus les taxes applicables, ainsi que d’autres dépenses et ils demanderont l’approbation du Tribunal de la Nouvelle-Écosse afin que le paiement soit fait conformément aux modalités établies dans leur convention de mandat professionnel.
La valeur totale du Règlement dépend du nombre de réclamations approuvées. Le montant maximum des honoraires qui pourra être réclamé par les Avocats du Groupe sera de 1 687 500$ (25% du montant de règlement maximum de 6 750 000$), plus les taxes applicables de 15%. Si le montant de règlement est inférieur au montant de règlement maximum, les Avocats du Groupe demanderont l’approbation d’un montant inférieur, à savoir 25% du montant de règlement versé, plus les taxes applicables de 15%. Le montant maximum des déboursés dont les Avocats du Groupe pourront demander l’approbation est évalué à environ 400 000$, ce qui représente les dépenses qu’ils ont engagées. Ce montant exclut les coûts futurs reliés à la publication des avis et à l’administration des réclamations, coûts pour lesquels les Défenderesses ont accepté de contribuer à la hauteur de 250 000$ du montant de règlement maximum.
S’OPPOSER AUX HONORAIRES ET DÉBOURSÉS ET POSSIBILITÉ DE SE PRÉSENTER DEVANT LE TRIBUNAL
Si vous désirez vous opposer aux honoraires réclamés par les Avocats du Groupe, vous devez transmettre votre opposition par écrit, portant comme référence Hfx. No. 315567, à la Cour suprême de la Nouvelle-Écosse, au Palais de justice situé au 1815, Upper Water Street, à Halifax (Nouvelle-Écosse), B3J 1S7 et en transmettre une copie à Wagners, à l’adresse indiquée ci-dessous, et ce, au plus tard le 15 janvier 2019. Vous pouvez également assister à l’audience d’approbation des honoraires des Avocats du Groupe et vous pourrez présenter vos observations oralement devant le Tribunal.
LES AVOCATS DU GROUPE
Il n’y a aucun frais afin de parler avec les Avocats du Groupe.
Cet avis a été approuvé par la Cour suprême de la Nouvelle-Écosse.
A Notice of Action and Statement of Claim were filed on August 18, 2009.
Various amendments to the claim have been filed, the most recent of which was on June 5, 2015.
The case was certified as a class proceeding on December 7, 2016.
The Defendants filed a Notice of Application for Leave to Appeal; the appeal is in abeyance until March 29, 2019.
Avandia is an oral diabetes medication and is manufactured by GlaxoSmithKline. Since its introduction in 1999 more than 6 million people have taken Avandia or Avandamet.
Avandia is used in the prevention of Type 2 diabetes in high-risk patients who are not controlled by diet and exercise alone, to reduce insulin resistance and to lower elevated blood glucose in patients. This class of drug is known as thiazolidinediones (TZDs) or glitazones. Avandia (Rosiglitazone) is a TZD and was approved for dispensing in Canada on March 30, 2000.
Drugs of this class can cause fluid retention that may progress to congestive heart failure. In addition to cardiovascular issues, other symptoms include swelling (edema), shortness of breath, weakness, fatigue, or excessive weight gain.
An Advisory was posted by Health Canada in November of 2001 indicating that there were safety concerns associated with the use of this class of drug. More recently new concerns have been raised about the link between Avandia and the risk of heart attack. More than one million prescriptions for Avandia were filled in Canada in 2006, ranking it the third most popular oral diabetes drug.
A study published in the New England Journal of Medicine in May, 2007 showed that the use of Avandia caused a significant increase in the risk of heart attack and possible death. The NEJM analysis of 42 studies revealed that there was a 43 per cent higher risk of heart attack for those taking Rosiglitazone compared to people taking other diabetes drugs or no diabetes medication at all. The report further stated that there is a 64 percent increase in the risk of death due to cardiovascular issues as a result of ingesting the drug. Dr. Steven Nissen, a cardiologist with the Cleveland Clinic, estimates that tens of thousands of deaths are attributable to Avandia.
On June 1, 2007, in response to the NEJM article, Health Canada issued a new warning. Physicians were advised about the use of Avandia in combination with other drugs. Health Canada also made recommendations for the handling of patients and indicated there was a need by the physician to weigh the overall
benefits of prescribing Avandia to their patients.
On June 6, 2007, the United States Food & Drug Administration announced it was calling for a black box warning on Avandia based on data that the diabetes drug is associated with an elevated risk of cardiovascular problems.
A further study published in the September 12 issue of the Journal of the American Medical Association indicated that one in 30 patients taking Avandia over the course of a year had heart failure and one in 220 had a heart attack.
Data obtained from Health Canada by the Winnipeg Free Press through an Access to Information request shows that 57 Canadians reported serious side-effects while taking Avandia and that 33 Canadians suffered heart failure, heart attack or stroke, and at least four people died.
Health officials were aware of heart risks linked to GlaxoSmithKline’s widely prescribed diabetes drug Avandia for a number of years. In 2002, for example, the FDA requested reports of congestive heart failure to be included on the label of Avandia.
GlaxoSmithKline has known of the cardiovascular risks of Avandia for an extended period of time. In August 2006, the company conducted a similar analysis of clinical trials and estimated the heart risk increased by 31 percent among Avandia patients.
GlaxoSmithKline continues to tout the safety of their product despite these finding and disclosures.
Recently there has been further controversy concerning GlaxoSmithKline and Avandia as a report surfaced that a medical expert, John Buse, M.D., was threatened with a lawsuit by GlaxoSmithKline’s executives when he initially raised doubts about the drug as far back as 1999.
Patients taking Avandia are encouraged not to stop taking Avandia without first consulting with their physicians.
Several lawsuits have been launched in Canada and the United States over the medication’s adverse effects, and drug safety regulators in both countries have been investigating its safety.
Wagners Law Firm have filed a Notice of Action and Statement of Claim with respect to the adverse effects caused by the prescription drug Avandia.
Update – March 13, 2017
The Defendants have filed their Defence to the class action. A copy of the Defence may be viewed under the Court Documents tab.
Update – February 23, 2017
On December 7, 2016, an Order for Certification was filed with the Supreme Court of Nova Scotia. The Order certified the action as a class proceeding pursuant to sections 4(3) and 7 of the Class Proceedings Act.
The Order defined the classes as:
(a) All persons in Canada, including their estates, who were prescribed and ingested Avandia (the “Primary Class”); and
(b) The spouses (including common-law spouses and same-sex spouses), children, grandchildren, parents, grandparents and siblings of deceased members of the Primary Class (the “Family Class”).
On December 22, 2016, the Defendants filed a Notice of Application for Leave to Appeal and Notice of Appeal (Interlocutory). These documents were filed with the Nova Scotia Court of Appeal by the Defendants (Appellants) in an effort to reverse and dismiss the certification of this action as a class proceeding.
On January 27, 2017, a Consent Order was filed with the Nova Scotia Court of Appeal which granted the Defendants (Appellants) application for leave to appeal from the Certification Order.
As such, the Defendants (Appellants) will have an opportunity to argue in an effort to reverse and dismiss the certification of this action as a class proceeding. Wagners, as Counsel and Respondents for the Plaintiffs and Class Members, will, in turn, argue to uphold the certification of this class proceeding.
Below is a schedule of events leading up to the day on which both Counsel for the Defendants (Appellants) and Plaintiffs (Respondents) will attend the Nova Scotia Court of Appeal to make their respective arguments.
March 10, 2017 – Due date for the Appellants’ Appeal Book
June 2, 2017 – Due date for the Appellants’ Factum (written submissions)
August 4, 2017 – Due date for the Respondents’ Factum (written submissions)
October 5, 2017 10:00 am – Full day appeal in the Nova Scotia Court of Appeal
Copies of the above noted Court filed documents will be made available under the Court Documents tab.
Update – June 2, 2016
On June 1, 2016, the Honourable Justice Michael Wood of the Supreme Court of Nova Scotia released his supplemental decision with respect to certification of the Avandia class action.
Justice Wood’s latest decision reaffirms the certification of this lawsuit as a class action proceeding.
Both the original certification decision and this latest supplemental decision may be viewed under the Court Documents tab.
Update – February 26, 2016
A copy of the Plaintiffs’ Supplemental Submissions was filed on today’s date with the Nova Scotia Supreme Court. Supporting affidavits were also filed pursuant to the direction of Justice Wood.
Update – January 19, 2016
On January 15, 2016, the Honourable Justice Michael Wood of the Supreme Court of Nova Scotia released his decision with respect to the Plaintiff’s motion to certify the lawsuit as a class action.
Justice Wood’s decision provides for a further 45 days for the Plaintiff to file additional evidence with a view to perfecting some minor deficiencies with the proceeding. Justice Wood has instructed the Plaintiff to supplement the evidence previously filed concerning the criterion of two or more class members required by s.7(1)(b) of the Class Proceedings Act and to file a revised list of common issues. Written submissions may also be provided. The Defendants will have a further 20 days to file any counter or responding evidence after the Plaintiff has submitted the supplemental information.
The decision of Justice Wood is available for viewing under the Court Documents tab. The additional evidence which will be filed by the Plaintiffs on or before the expiry of the 45 day extension will also be made available once it has been sent to Justice Wood.
Update – December 10, 2015
We continue to await the release of the decision of the Honourable Justice Michael Wood with respect to the Plaintiff’s motion to certify the proceeding as a class action.
Once released, the decision will be made available under the Court Documents tab.
Update – September 23, 2015
Counsel appeared before the Honourable Justice Michael Wood for four days last week for the hearing of the Plaintiffs’ motion for certification.
Justice Wood has reserved his decision. Once released, a copy of the the decision will be available for viewing under the Court Documents tab.
Update – September 15, 2015
The Plaintiffs’ motion for certification, which commences today, will be live streamed at the Nova Scotia Courts website.
Interested persons may view the proceedings at:
Update – September 4, 2015
The Plaintiffs’ motion for certification of the proposed class proceeding as a class action is scheduled for September 15 – 18, 2015 in the Nova Scotia Supreme Court in Halifax.
Documentation pertaining to the motion for certification may be viewed under the Court Documents tab.
Update – May 26, 2015
A case management conference was held today before the Honourable Justice Wood. The following dates have been scheduled for the filing of the Briefs with respect to the certification motion scheduled for hearing over 4 days, from September 15 to 18, 2015:
- July 3, 2015 – Applicant’s Certification Brief
- August 7, 2015 – Respondent’s Certification Brief
- August 21, 2015 – Applicant’s Reply Brief, if any;
Justice Wood also ordered that if there are any evidentiary objections to the admissibility of the evidence which has been filed, any objections must be raised no later than June 30, 2015.
Update – April 27, 2015
All Counsel are in the process of scheduling dates for examinations of the experts who have provided affidavits regarding certification concerning the Avandia class action.
Update – March 27, 2015
The Defendants have provided Wagners with copies of three affidavits which they have filed with respect to certification.
The affidavits may be viewed under the Court Documents tab.
Update – February 25, 2015
Wagners have filed motion documents with the Supreme Court of Nova Scotia today with respect to amending the Statement of Claim.
The documents are available under the Court Documents tab.
Update – January 29, 2015
The case management conference before Justice Wood was held on January 28th via conference call.
Issues concerning amendments to the Statement of Claim and certification evidence were discussed.
Justice Wood scheduled the date of March 12, 2015 for the hearing of the Plaintiff`s motion to amend the Statement of Claim should an agreement with the Defendants not be reached. Various filing deadlines were scheduled.
The deadline for the filing of the Defendants evidentiary record on certification is March 27, 2015, with discovery examinations to be completed by May 22, 2015.
Update – January 20, 2015
The Defendants’ have sent correspondence to the Court requesting that a date be scheduled for a case management conference before Justice Wood.
Update – January 14, 2015
The Defendants will be filing their response to the Plaintiffs’ certification documents in the near future with respect to the Avandia class action.
Copies of the Plaintiffs’ certification documents may be found under the Court Documents tab. Copies of the Defendants’ materials will also be uploaded once they have been received.
Update – July 14, 2014
On May 21, 2014, Counsel appeared before Justice Wood for the hearing of the Defendants’ motions to strike out an affidavit exhibit and to have the Representative Plaintiffs disclose medical records.
On July 9, 2014, Justice Wood released his decision in favour of the Defendants. A copy of the decision and other documents pertaining to the motions may be found under the Court Documents tab.
Update – January 20, 2014
On January 8, 2014, a further case management conference call was held before Justice Wood.
At that time, dates were assigned for preliminary motions which are scheduled for May 21, 2014. A schedule of the filing timelines was also arranged as follows:
- March 21, 2014 – Notice of Motions and Submissions
- April 11, 2014 – Reply Submissions
- April 25, 2014 – Rebuttal Submissions
At present it is undetermined what the particulars of the motions or what their scope may be.
The relevant documents to be filed by the parties, will be made available for review under the Court Documents tab.
Update – November 7, 2013
A case management conference call was held before the Honourable Justice Michael Wood on November 1, 2013 to discuss the Nova Scotia proceedings as well as proceedings in other Provinces of Canada. Counsel for the Defendants was also involved in the call.
Lawyers from Wagners will be reappearing before Justice Wood on January 8, 2014 for a further case management conference call.
Update – August 21, 2013
A Justice with the Supreme Court of Newfoundland and Labrador has been assigned to case manage the NL proceedings. The Order has been uploaded and may be found under the Court Documents tab.
Update – June 20, 2013
Wagners Law Firm has filed its Notice of Action and Statement of Claim with the Court of Queen`s Bench in Moncton, New Brunswick on today’s date. A copy of the pleading is available for viewing under the Court Documents tab.
Update – May 16, 2013
We filed a Statement of Claim in the Province of Prince Edward Island on today’s date. A copy of the proposed class proceeding may be located under the Court Documents tab.
Update – May 10, 2013
We filed a Statement of Claim in the Province of Newfoundland and Labrador on today’s date. A copy of the newly filed proposed class action may be viewed under the Court Documents tab.
Update – December 5, 2012
We understand that Ontario Counsel are in the process of obtaining expert reports for certification purposes.
Update – March 7, 2012
We are continuing our efforts to develop our certification motion documents.
Update – February 13, 2012
The litigation concerning this medication remains ongoing. Procedurally, the next process in the proceeding will be to file our documentation so that we may obtain a date for the hearing of our motion to certify the proceeding as a class action. All proposed class proceedings must be certified by the Court if they are to proceed as a class action. If we are successfully certified, then the case will continue in accordance with the Nova Scotia Class Proceedings Act.
Copies of our certification motion documents will be made available under the Court Documents tab page once they have been filed with the Court.
Update – July 27, 2010
An Amended Statement of Claim was filed with the Nova Scotia Supreme Court today. The amended claim may be viewed under the Court Documents tab.
Update – August 18, 2009
Wagners commenced a proposed class proceeding on behalf of individuals affected by the use of the Avandia medication. Read the Press Release here.
Update – June 30, 2009
Wagners is continuing to explore the potential of commencing a proposed class proceeding with respect to the adverse effects of Avandia.
The following documents concerning the class action which Wagners has filed as a result of the serious and adverse side effects associated with the use of the diabetes medication Avandia are also available for viewing in PDF format:
- June 1, 2016 – Supplemental Decision re: Certification
- January 15, 2016 – Decision re: Certification
- June 5, 2015 – 2nd Fresh Amended Statement of Claim
- July 9, 2014 – Decision re: Strike and Disclosure
- June 20, 2013 – Notice of Action & Statement of Claim (NB)
- May 16, 2013 – Statement of Claim (PEI)
- May 10, 2013 – Statement of Claim (NL)
- July 27, 2010 – Amended Statement of Claim (NS)
- August 18, 2009 – Notice of Action & Statement of Claim (NS)